Inhibrx concludes Phase I dose escalation of solid tumour therapy
The company received $60m from Oxford Finance under a Loan and Security Agreement.

The company received $60m from Oxford Finance under a Loan and Security Agreement.
Dose-limiting toxicity, maximum tolerated dose and recommended Phase II dose of oral APG-5918 will be analysed in the trial.
The company plans to commence subject enrolment in the trial in the fourth quarter of this year.
The trial will analyse the safety and efficacy of ASC22 along with ART versus placebo in HIV-1 patients.
Curavit’s decentralised clinical trial capabilities make it ideal for prescription and non-prescription DTx studies.
Increased neutralising antibody levels against all variants, including Omicron BA2, and memory response were observed in subjects.
Analysing the decline in OCD symptoms for up to 12 weeks following a single dose of SYNP-101 is the…
The open-label, first-in-human, single ascending dose trial will analyse KIO-301 in individuals with retinitis pigmentosa.
In the trial, 64.7% of the trial subjects attained an ORR, which is the primary efficacy endpoint of the…
Thank you for subscribing to Clinical Trials Arena